Biolinq Revolutionizes Glucose Monitoring with $58M Funding Boost

Biolinq, a San Diego-based healthcare technology company, secures $58M in funding to advance its innovative continuous glucose monitoring patch. Led by Alpha Wave Ventures, the funding will support completion of a pivotal clinical trial and FDA submission for the intradermal sensor. CEO Rich Yang aims to provide a simple, discreet, and reliable solution for metabolic health monitoring without the need for finger pricking. With a mission to improve metabolic health for more people, Biolinq's technology approach is set to revolutionize glucose monitoring.